STP2

About STALICLA

STALICLA is a Geneva-based biotech founded in 2017, developing precision therapeutics for complex brain disorders, starting with Autism Spectrum Disorder (ASD). The company's core asset is its DEPI (Drug Efficacy Prediction Interface) platform, a biology-driven, AI-enhanced system that deconvolutes heterogeneous disorders into biologically defined subgroups to match them with targeted treatments. Its most advanced asset, STP1 (a combination of two approved drugs), is in Phase 2 trials for a specific ASD subgroup identified by DEPI. STALICLA represents a novel, data-driven approach to neuropsychiatry, aiming to deliver the first precision medicine for ASD.

Therapeutic Areas

Other Autism Spectrum Disorder (specific subgroup) Drugs